文献速递急性肾损伤遗传性与小管间质肾病

依库珠单抗预防性用于吉西他滨诱导性血栓性微血管病中系统性再挑战吉西他滨:一例病例报告

Eculizumab Prophylaxis for Systematic Rechallenging Gemcitabine in Gemcitabine-Induced Thrombotic Microangiopathy: A Case Report.
PubMed 文献 · Am J Kidney Dis · 2025-08-16

本文报告一例72岁转移性胰腺腺癌女性患者,在吉西他滨联合白蛋白结合型紫杉醇治疗期间发生严重血栓性微血管病(TMA),肾活检证实TMA,停用吉西他滨并转为FOLFIRINOX方案后病情稳定但肿瘤影像学进展。在终末补体阻断预防下再挑战吉西他滨,给予依库珠单抗900 mg静脉注射每周1次共4次,随后重新引入吉西他滨联合白蛋白结合型紫杉醇,3个月内4个治疗周期未见GITMA复发。

要点

  • 吉西他滨诱导性TMA是罕见但破坏性并发症,尤其累积剂量超过20,000 mg/m2时。
  • 本例在依库珠单抗预防下再挑战吉西他滨,3个月内4个周期未见TMA复发。
  • 依库珠单抗的最佳剂量、时机及长期结局尚需进一步研究确定。

核心结论

  • 本病例表明依库珠单抗在预防复发性吉西他滨诱导性血栓性微血管病方面可能具有作用,使转移性胰腺腺癌患者得以继续含吉西他滨的治疗。
  • 尚需进一步研究以确定依库珠单抗的最佳剂量、时机及长期结局。

研究设计与样本

  • 病例报告:一例72岁转移性胰腺腺癌女性患者。

主要发现

  • 患者在吉西他滨联合白蛋白结合型紫杉醇治疗期间发生严重血栓性微血管病,表现为血小板减少、微血管病性溶血性贫血和急性肾损伤。
  • 肾活检证实TMA,停用吉西他滨并转为FOLFIRINOX后肾脏和血液学参数改善、病情稳定,但肿瘤影像学进展。
  • 在终末补体阻断预防下再挑战吉西他滨,依库珠单抗900 mg静脉注射每周1次共4次,随后重新引入吉西他滨联合白蛋白结合型紫杉醇。
  • 3个月内4个治疗周期未见GITMA复发迹象,肾功能稳定,溶血标志物正常。

关键数值与推荐

  • 吉西他滨累积剂量超过20,000 mg/m2时GITMA风险尤其高。
  • 依库珠单抗900 mg静脉注射每周1次共4次用于终末补体阻断预防。

临床怎么用

  • 作者认为依库珠单抗在预防复发性GITMA方面可能具有作用,使患者得以继续含吉西他滨的治疗。
  • 作者指出尚需进一步研究以确定依库珠单抗的最佳剂量、时机及长期结局。

局限性

  • 原文为病例报告,进一步研究尚需开展以确定依库珠单抗的最佳剂量、时机及长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gemcitabine-induced thrombotic microangiopathy (GITMA) is a rare yet devastating complication in patients receiving gemcitabine, especially at cumulative doses above 20,000 mg/m2. We report the case of a 72-year-old woman with metastatic pancreatic adenocarcinoma who developed severe thrombotic microangiopathy (TMA) during gemcitabine and nab-paclitaxel therapy. Her initial presentation included thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney injury. A kidney biopsy confirmed TMA and, given the high likelihood this was related to gemcitabine, therapy was discontinued and the patient was transitioned to folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX). Although the patient stabilized with improved renal and hematologic parameters, her cancer progressed radiographically. Given her good performance status and the need for effective tumor control, a decision was made to rechallenge with gemcitabine under prophylactic terminal complement blockade. She received eculizumab 900 mg intravenously for 4 weekly doses, followed by reintroduction of gemcitabine and nab-paclitaxel. Over 4 treatment cycles given during a 3-month period, the patient showed no signs of GITMA recurrence, maintaining stable renal function and normal hemolysis markers. This case demonstrates the potential role of eculizumab in preventing recurrent GITMA, allowing continued gemcitabine-based therapy for metastatic pancreatic adenocarcinoma. Further research is warranted to define optimal dosing and timing of eculizumab and long-term outcomes.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Chewcharat A, Wang M, Gupta S, et al. Eculizumab Prophylaxis for Systematic Rechallenging Gemcitabine in Gemcitabine-Induced Thrombotic Microangiopathy: A Case Report. Am J Kidney Dis. 2025. PMID: 40825470. doi:10.1053/j.ajkd.2025.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。